Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Tapentadol phosphate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for The full name of your medicine is 'Tapentadol Aspire 25mg, 50mg, 100mg, 150mg, 200mg or 250mg prolonged release tablets'. It is referred to as 'this medicine' in the rest of this leaflet. This medicine has been prescribed for you for the treatment of severe long-term pain that can only be adequately managed with an opioid painkiller in adults. This medicine contains tapentadol which belongs to a class of medicines called opioids, which are 'pain relievers'. This medicine has been prescribed to you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely.
e this medicine Do not take this medicine:
this medicine Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Before starting treatment and regularly during treatment, your doctor will discuss with you what you may expect from using tapentadol, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also "If you stop taking this medicine" below). Your doctor will change the dose and time between doses of this medicine according to your pain level and your needs. Generally, the lowest pain-relieving dose should be taken. Adults The usual dose is 1 tablet every 12 hours. Total daily doses of this medicine greater than 500mg tapentadol are not recommended. Your doctor may prescribe a different, more appropriate dose or timing of dosing, if this is necessary for you. If you feel that the effect of these tablets is too strong or weak, talk to your doctor or pharmacist. Elderly patients In elderly patients (above 65 years) usually no dose adjustment is necessary. However, the excretion of tapentadol may be delayed in some patients of this age group. If this applies to you, your doctor may adjust your dose or time between doses if required. Patients with liver or kidney disease (insufficiency) Do not take this medicine if you have severe liver or kidney problems. If you have moderate liver problems, your doctor will adjust your dose or time between doses. If you have mild liver problems or mild to moderate kidney problems, a dose adjustment is not required. Children and adolescents This medicine is not suitable for children and adolescents below the age of 18 years. How and when should you take this medicine This medicine is for oral use. Swallow the tablets with a glass of water. You may take the tablets either on an empty stomach or with food. Do not chew, break or crush the tablet, as it may result in overdose due to quick release of tapentadol in your body. The score line is not intended for breaking the tablet. The empty shell of the tablet may not be digested completely and thus be seen in your stool. This should not worry you, since the drug (active substance) of the tablet has already been absorbed in your body and what you see is just the empty shell. How long should you take this medicine Do not take the tablets for longer than your doctor has told you. Your prescriber should have discussed with you, how long the course of tablets will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. If you take more of this medicine than you should Taking too much of this medicine may be life-threatening. Immediate medical advice should be sought in the event of an overdose, even if you feel well. Very high doses of this medicine may cause the following:
directly via the Yellow Card Scheme at: www.mhra.gov.uk/ yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
5
this medicine
Store this medicine in a safe and secure storage space, where other people cannot access it. It can cause serious harm and be fatal to people when it has not been prescribed for them. Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and the blister. The expiry date refers to the last day of that month. This medicinal product does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What this medicine looks like and contents of the pack
This leaflet is available in formats suitable for the blind and partially sighted. Please contact Aspire Pharma Ltd via telephone: (+44) 01730 231148 or email: [email protected] for more information. 1010583 – P4.1
Artwork for: Product name: Size: PL/PA no: Type: Artwork dimensions: Reason for request: Version no: Date of revision: Colours: Font(s): A/W software: Laetus Code:
Aspire Pharma Limited Tapentadol prolonged-release tablets 25mg/50mg/100mg/150mg/200mg/250mg PL35533/0189-194 Leaflet 200mm x 600mm Text update P4.1 22.10.25 As swatches Strada Pro Indesign CC XXX
Black
4 Possible side effects
6
Like all medicines, this medicine can cause side effects, although not everybody gets them. Important side effects or symptoms to look out for and what to do if you are affected:
What this medicine contains The active ingredient is tapentadol. Each Tapentadol Aspire 25mg prolonged-release tablet contains 25mg tapentadol (as phosphate). Each Tapentadol Aspire 50mg prolonged-release tablet contains 50mg tapentadol (as phosphate). Each Tapentadol Aspire 100mg prolonged-release tablet contains 100mg tapentadol (as phosphate). Each Tapentadol Aspire 150mg prolonged-release tablet contains 150mg tapentadol (as phosphate). Each Tapentadol Aspire 200mg prolonged-release tablet contains 200mg tapentadol (as phosphate). Each Tapentadol Aspire 250mg prolonged-release tablet contains 250mg tapentadol (as phosphate). The other ingredients are:
Other side effects that may occur: Very common (may affect more than 1 in 10 people)
Tapentadol Aspire 250mg prolonged-release tablets comes as tablet containing 250mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Tapentadol Aspire 250mg prolonged-release tablets is tapentadol phosphate.
Medicines with the same active substance, strength and form include: Ationdo SR 250mg prolonged release tablets PL 50414/0009, LUPAXIS 250 mg Prolonged-release Tablets, Palexia SR 250 mg prolonged-release tablets. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Tapentadol Aspire 250mg prolonged-release tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
This medicine is indicated for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics.
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with tapentadol in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).
Posology
The dosing regimen should be individualised according to the severity of pain being treated, the previous treatment experience and the ability to monitor the patient.
This medicine should be taken twice daily, approximately every 12 hours.
Initiation of therapy
Initiation of therapy in patients currently not taking opioid analgesics.
Patients should start treatment with single doses of 50 mg tapentadol as prolonged-release tablet administered twice daily
Initiation of therapy in patients currently taking opioid analgesics
When switching from opioids to this medicine and choosing the initial dose, the nature of the previous medicinal product, administration and the mean daily dose should be taken into account. This may require higher initial doses of Tapentadol SR for patients currently taking opioids compared to those not having taken opioids before initiating therapy with this medicine.
Titration and maintenance
After initiation of therapy the dose should be titrated individually to a level that provides adequate analgesia and minimises undesirable effects under the close supervision of the prescribing physician.
Experience from clinical trials has shown that a titration regimen in increments of 50 mg tapentadol as prolonged-release tablet twice daily every 3 days was appropriate to achieve adequate pain control in most of the patients.
Total daily doses of this medicine greater than 500 mg tapentadol have not yet been studied and are therefore not recommended.
Duration of treatment
Tapentadol should not be used longer than necessary.
Renal Impairment
In patients with mild or moderate renal impairment a dosage adjustment is not required (see section 5.2). This medicine has not been studied in controlled efficacy trials in patients with severe renal impairment, therefore the use in this population is not recommended (see sections 4.4 and 5.2).
Hepatic Impairment
In patients with mild hepatic impairment a dosage adjustment is not required (see section 5.2).
This medicine should be used with caution in patients with moderate hepatic impairment. Treatment in these patients should be initiated at the lowest available dose strength, i.e. 50 mg tapentadol as prolonged-release tablet, and not be administered more frequently than once every 24 hours. At initiation of therapy a daily dose greater than 50 mg tapentadol as prolonged-release tablet is not recommended. Further treatment should reflect maintenance of analgesia with acceptable tolerability (see sections 4.4 and 5.2).
This medicine has not been studied in patients with severe hepatic impairment and therefore, use in this population is not recommended (see sections 4.4 and 5.2).
Elderly patients (persons aged 65 years and over)
In general, a dose adaptation in elderly patients is not required. However, as elderly patients are more likely to have decreased renal and hepatic function, care should be taken in dose selection as recommended (see sections 4.2 and 5.2).
Paediatric Patients
The safety and efficacy of this medicine in children and adolescents below 18 years of age has not yet been established. Therefore, this medicine is not recommended for use in this population.
Method of administration
This medicine has to be taken whole, not divided or chewed, to ensure that the prolonged-release mechanism is maintained.
For oral use.
This medicine should be taken with sufficient liquid. This medicine can be taken with or without food.
The shell (matrix) of the tapentadol tablet may not be digested completely and therefore it can be eliminated and seen in the patient's stool. However, this finding has no clinical relevance, since the active substance of the tablet will have already been absorbed.
Treatment goals and discontinuation
Before initiating treatment with tapentadol, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with tapentadol, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).
This medicine is contraindicated:
• in patients with hypersensitivity to tapentadol or to any of the excipients listed in section 6.1.
• in situations where active substances with mu-opioid receptor agonist activity are contraindicated, i.e. patients with significant respiratory depression (in unmonitored settings or the absence of resuscitative equipment), and patients with acute or severe bronchial asthma or hypercapnia
• in any patient who has or is suspected of having paralytic ileus
• in patients with acute intoxication with alcohol, hypnotics, centrally acting analgesics, or psychotropic active substances (see section 4.5)
Tolerance and Opioid Use Disorder (abuse and dependence)
Tolerance, physical and psychological dependence, and opioid use disorder (OUD) may develop upon repeated administration of opioids such as tapentadol. A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of opioids may result in overdose and/or death.
The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).
Before initiating treatment with tapentadol and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.
Patients will require monitoring for signs of drug-seeking behaviour (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.
Do not use for acute post-operative pain owing to the increased risk of persistent post-operative opioid use (PPOU).
Risk from concomitant use of sedating medicinal products such as benzodiazepines or related substances
Concomitant use of this medicine and sedating medicinal products such as benzodiazepines or related substances may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedating medicinal products should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe this medicine concomitantly with sedating medicinal products, the reduction of dose of one or both agents should be considered, and the duration of the concomitant treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
Respiratory Depression
At high doses or in mu-opioid receptor agonist sensitive patients, this medicine may produce dose-related respiratory depression. Therefore, this medicine should be administered with caution to patients with impaired respiratory functions. Alternative non-mu-opioid receptor agonist analgesics should be considered and this medicine should be employed only under careful medical supervision at the lowest effective dose in such patients. If respiratory depression occurs, it should be treated as any mu-opioid receptor agonist-induced respiratory depression (see section 4.9).
Do not use for acute post-operative pain owing to the increased risk of opioid-induced ventilatory impairment (OIVI).
Head Injury and Increased Intracranial Pressure
Tapentadol SR should not be used in patients who may be particularly susceptible to the intracranial effects of carbon dioxide retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. Analgesics with mu-opioid receptor agonist activity may obscure the clinical course of patients with head injury. This medicine should be used with caution in patients with head injury and brain tumours.
Seizures
This medicine has not been systematically evaluated in patients with a seizure disorder, and such patients were excluded from clinical trials. However, like other analgesics with mu-opioid agonist activity this medicine is not recommended in patients with a history of a seizure disorder or any condition that would put the patient at risk of seizures. In addition, tapentadol may increase the seizure risk in patients taking other medicinal products that lower the seizure threshold (see section 4.5).
Renal Impairment
This medicine has not been studied in controlled efficacy trials in patients with severe renal impairment, therefore the use in this population is not recommended (see section 4.2 and 5.2).
Hepatic Impairment
Subjects with mild and moderate hepatic impairment showed a 2-fold and 4.5-fold increase in systemic exposure, respectively, compared with subjects with normal hepatic function. Tapentadol SR should be used with caution in patients with moderate hepatic impairment (see section 4.2 and 5.2), especially upon initiation of treatment.
This medicine has not been studied in patients with severe hepatic impairment and therefore, use in this population is not recommended (see sections 4.2 and 5.2).
Use in Pancreatic/Biliary Tract Disease
Active substances with mu-opioid receptor agonist activity may cause spasm of the sphincter of Oddi. this medicine should be used with caution in patients with biliary tract disease, including acute pancreatitis.
Sleep-related breathing disorders
Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.
Mixed opioid agonists/antagonists
Care should be taken when combining this medicine with mixed mu-opioid agonist/antagonists (like pentazocine, nalbuphine) or partial mu-opioid agonists (like buprenorphine). In patients maintained on buprenorphine for the treatment of opioid dependence, alternative treatment options (like e.g. temporary buprenorphine discontinuation) should be considered, if administration of full mu-agonists (like tapentadol) becomes necessary in acute pain situations. On combined use with buprenorphine, higher dose requirements for full mu-receptor agonists have been reported and close monitoring of adverse events such as respiratory depression is required in such circumstances.
Centrally-acting medicinal products/central nervous system (CNS) depressants, including alcohol and CNS depressant narcotic drugs
The concomitant use of Tapentadol with sedating medicinal products such as benzodiazepines or other respiratory or CNS depressants (other opioids, antitussives or substitution treatments, barbiturates, antipsychotics, H1-antihistamines, alcohol) increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. Therefore, when a combined therapy of Tapentadol SR with a respiratory or CNS depressant is contemplated, the reduction of the dose of one or both agents should be considered and the duration of the concomitant use should be limited (see section 4.4). The concomitant use of opioids and gabapentinoids (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression and death.
Mixed opioid agonists/antagonists
Care should be taken when combining his medicine with mixed mu-opioid agonist/antagonists (like pentazocine, nalbuphine) or partial mu-opioid agonists (like buprenorphine) (see also section 4.4).
This medicine can induce convulsions and increase the potential for selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, antipsychotics and other medicinal products that lower the seizure threshold to cause convulsions.
There have been reports of serotonin syndrome in a temporal connection with the therapeutic use of tapentadol in combination with serotoninergic medicinal products such as selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants.
Serotonin syndrome is likely when one of the following is observed:
• Spontaneous clonus
• Inducible or ocular clonus with agitation or diaphoresis
• Tremor and hyperreflexia
• Hypertonia and body temperature > 38°C and inducible ocular clonus.
Withdrawal of the serotoninergic medicinal products usually brings about a rapid improvement. Treatment depends on the nature and severity of the symptoms.
The major elimination pathway for tapentadol is conjugation with glucuronic acid mediated via uridine diphosphate transferase (UGT) mainly UGT1A6, UGT1A9 and UGT2B7 isoforms. Thus, concomitant administration with strong inhibitors of these isoenzymes (e.g. ketoconazole, fluconazole, meclofenamic acid) may lead to increased systemic exposure of tapentadol (see section 5.2).
For patients on tapentadol treatment, caution should be exercised if concomitant drug administration of strong enzyme inducing drugs (e.g. rifampicin, phenobarbital, St John's Wort (hypericum perforatum) starts or stops, since this may lead to decreased efficacy or risk for adverse effects, respectively.
Treatment with this medicine should be avoided in patients who are receiving monoamine oxidase (MAO) inhibitors or who have taken them within the last 14 days due to potential additive effects on synaptic noradrenaline concentrations which may result in adverse cardiovascular events, such as hypertensive crisis.
Anticholinergics
Concomitant administration of tapentadol with anticholinergics or medications with anticholinergic activity (e.g. tricyclic antidepressants, antihistamines, antipsychotics, muscle relaxants, anti-Parkinson drugs) may result in increased anticholinergic adverse effects.
Pregnancy
There is a very limited amount of data from the use in pregnant women.
Studies in animals have not shown teratogenic effects. However, delayed development and embryotoxicity were observed at doses resulting in exaggerated pharmacology (mu-opioid related CNS effects related to dosing above the therapeutic range). Effects on the postnatal development were already observed at the maternal NOAEL (see section 5.3).
This medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate Neonatal opioid withdrawal syndrome can be life-threatening if not recognised and treated. An antidote for the newborn should be readily available. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
Labour and Delivery
The effect of tapentadol on labour and delivery in humans is unknown. This medicine is not recommended for use in women during and immediately before labour and delivery. Due to the mu-opioid receptor agonist activity of tapentadol, new-born infants whose mothers have been taking tapentadol should be monitored for respiratory depression. Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.
Breast-feeding
There is no information on the excretion of tapentadol in human milk. From a study in rat pups suckled by dams dosed with tapentadol it was concluded that tapentadol is excreted via milk (see section 5.3). Therefore, a risk to the suckling child cannot be excluded.
Administration to nursing women is not recommended as tapentadol may be secreted in breast milk and may cause respiratory depression in the infant. This medicine should not be used during breast feeding.
Fertility
No human data on the effect of This medicine on fertility are available. In a fertility and early embryonic development study, no effects on reproductive parameters were observed in male or female rats (see section 5.3).
This medicine may have major influence on the ability to drive and use machines, because it may adversely affect central nervous system functions (see section 4.8). This has to be expected especially at the beginning of treatment, when any change of dosage occur as well as in connection with the use of alcohol or tranquilisers (see section 4.4). Patients should be cautioned as to whether driving or use of machines is permitted.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive if you are unfit to drive
• However, you would not be committing an offence (called 'statutory defence') if:
- The medicine has been prescribed to treat a medical or dental problem and
- You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and
- It was not affecting your ability to drive safely.
The adverse drug reactions that were experienced by patients in the placebo controlled trials performed with this medicine were predominantly of mild and moderate severity. The most frequent adverse drug reactions were in the gastrointestinal and central nervous system (nausea, dizziness, constipation, headache and somnolence).
The table below lists adverse drug reactions that were identified from clinical trials performed with this medicine and from post-marketing environment. They are listed by class and frequency. Frequencies are defined as very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare ((≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
ADVERSE DRUG REACTIONS
System Organ Class
Frequency
Very common
Common
Uncommon
Rare
Unknown
Immune system disorders
Drug hypersensitivity*
Metabolism and nutrition disorders
Decreased appetite
Weight decreased
Psychiatric disorders
Anxiety, Depressed mood, Sleep disorder, Nervousness, Restlessness
Disorientation, Confusional state, Agitation, Perception disturbances, Abnormal dreams, Euphoric mood
Thinking Abnormal, Drug Dependence (see section 4.4)
Delirium**
Nervous system disorders
Dizziness, Somnolence, Headache
Disturbance in attention, Tremor, Muscle contractions involuntary
Depressed level of consciousness, Memory impairment, Mental impairment, Syncope, Sedation, Balance disorder, Dysarthria, Hypoaesthesia, Paraesthesia
Convulsion, Presyncope, Coordination abnormal
Eye disorders
Visual disturbance
Cardiac disorders
Heart rate increased, Heart rate decreased, Palpitations
Vascular disorders
Flushing
Blood pressure decreased
Respiratory, thoracic and mediastinal disorders
Dyspnoea
Respiratory depression
Gastrointestinal disorders
Nausea, Constipation
Vomiting, Diarrhoea, Dyspepsia
Abdominal discomfort
Impaired gastric emptying
Skin and subcutaneous tissue disorders
Pruritus, Hyperhidrosis, Rash
Urticaria
Renal and urinary disorders
Urinary hesitation, Pollakiuria
Reproductive system and breast disorders
Sexual dysfunction
General disorders and administration site conditions
Asthenia, Fatigue, Feeling of body temperature change, Mucosal dryness, Oedema
Drug withdrawal syndrome, Feeling abnormal, Irritability
Feeling drunk, Feeling of relaxation
* Post-marketing rare events of angioedema, anaphylaxis and anaphylactic shock have been reported.
** Post marketing cases of delirium were observed in patients with additional risk factors such as cancer and advanced age.
Clinical trials performed with this medicine with patient exposure up to 1 year have shown little evidence of withdrawal symptoms upon abrupt discontinuations and these were generally classified as mild, when they occurred. Nevertheless, physicians should be vigilant for symptoms of withdrawal (see section 4.2) and treat patients accordingly should they occur.
The risk of suicidal ideation and suicides committed is known to be higher in patients suffering from chronic pain. In addition, substances with a pronounced influence on the monoaminergic system have been associated with an increased risk of suicidality in patients suffering from depression, especially at the beginning of treatment. For tapentadol data from clinical trials and post-marketing reports do not provide evidence for an increased risk.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.
Symptoms
Human experience with overdose of tapentadol is limited. Preclinical data suggest that symptoms similar to those of other centrally acting analgesics with muopioid receptor agonist activity are to be expected upon intoxication with tapentadol. In principle, these symptoms include, referring to the clinical setting, in particular miosis, vomiting, cardiovascular collapse, consciousness disorders up to coma, convulsions and respiratory depression up to respiratory arrest that may be fatal.
Management
Management of overdose should be focused on treating symptoms of mu-opioid agonism. Primary attention should be given to re-establishment of a patent airway and institution of assisted or controlled ventilation when overdose of tapentadol is suspected.
Pure opioid receptor antagonists such as naloxone are specific antidotes to respiratory depression resulting from opioid overdose. Respiratory depression following an overdose may outlast the duration of action of the opioid receptor antagonist. Administration of an opioid receptor antagonist is not a substitute for continuous monitoring of airway, breathing, and circulation following an opioid overdose. If the response to opioid receptor antagonists is suboptimal or only brief in nature, an additional dose of antagonist (e.g. naloxone) should be administered as directed by the manufacturer of the product.
Gastrointestinal decontamination may be considered in order to eliminate unabsorbed active substance. Gastrointestinal decontamination with activated charcoal or by gastric lavage may be considered within 2 hours after intake. Before attempting gastrointestinal decontamination, care should be taken to secure the airway.
Ask anything about Tapentadol Aspire 250mg prolonged-release tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.